Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

Blackhawk Growth Corp Acquires Trip Pharma Inc.

October 13, 2020

Healthcare Services

Blackhawk Growth Corp. completed the acquisition of all outstanding shares of Trip Pharma Inc., an Edmonton-based psychedelic development and wellness company led by Dr. Krista Leicht. The transaction was satisfied largely with issuance of common shares to Trip Pharma shareholders and brings Trip Pharma into Blackhawk's existing healthcare/cannabis investment portfolio as it pursues clinical research and a psychiatric research clinic focused on psilocybin-based therapies.

Enveric Biosciences Acquires MagicMed Industries

May 24, 2021

Biotechnology

Enveric Biosciences entered into a definitive all-stock agreement to acquire MagicMed Industries, a Calgary-based biotechnology company focused on psychedelic-derived drug discovery, in an amalgamation that will make MagicMed an indirect wholly owned subsidiary of Enveric. The deal expands Enveric’s pipeline beyond cannabinoids into psychedelic-derived molecules (psilocybin, DMT derivatives, etc.), includes issuance of Enveric common stock and equity awards to MagicMed shareholders, and contemplates leadership changes with Dr. Joseph Tucker named CEO upon closing.

MediPharm Labs Corp. Acquires VIVO Cannabis Inc.

April 1, 2023

Pharmaceuticals

Effective April 1, 2023, MediPharm Labs Corp. completed an all-equity arrangement to acquire all outstanding shares of VIVO Cannabis Inc., making VIVO a wholly-owned subsidiary. Under the arrangement, former VIVO shareholders received 0.2910 MediPharm common shares per VIVO share and MediPharm issued approximately 107,930,964 shares as consideration; VIVO shares are expected to be delisted from the Toronto Stock Exchange.

Isracann Biosciences to Acquire Praesidio Health

February 23, 2022

Biotechnology

Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.